XML 186 R122.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Selected Quarterly Financial Information [Abstract]                      
Product, net $ 2,712.4 $ 2,622.5 $ 2,639.7 $ 2,380.1 $ 2,502.9 $ 2,539.6 $ 2,466.0 $ 2,309.4 $ 10,354.7 $ 9,817.9 $ 9,188.5
Revenues from anti-CD20 therapeutic programs 415.0 406.5 397.1 340.6 318.2 317.6 349.2 329.5 1,559.2 1,314.5 1,339.2
Other 179.6 48.8 41.6 90.0 50.9 98.6 79.0 87.9 360.0 316.4 236.1
Total revenues 3,307.0 3,077.8 3,078.4 2,810.7 2,872.0 2,955.8 2,894.2 2,726.8 12,273.9 11,448.8 10,763.8
Gross Profit [1] 2,797.8 2,707.8 2,712.2 2,426.1 2,493.5 2,538.9 2,523.9 2,413.8 10,643.9 9,970.1  
Net income (166.3) 1,226.1 862.8 747.5 647.9 1,030.2 1,048.4 969.2 2,670.1 3,695.7 3,593.2
Net income attributable to Biogen Idec Inc $ (297.4) $ 1,226.1 $ 862.8 $ 747.6 $ 649.2 $ 1,032.9 $ 1,049.8 $ 970.9 $ 2,539.1 $ 3,702.8 $ 3,547.0
Basic earnings per share attributable to Biogen Inc. $ (1.41) $ 5.80 $ 4.07 $ 3.47 $ 3.00 $ 4.72 $ 4.79 $ 4.44 $ 11.94 $ 16.96 $ 15.38
Diluted earnings per share attributable to Biogen Inc. $ (1.40) $ 5.79 $ 4.07 $ 3.46 $ 2.99 $ 4.71 $ 4.79 $ 4.43 $ 11.92 $ 16.93 $ 15.34
Basic earnings per share attributable to Biogen Inc. 211.5 211.4 211.9 215.6 216.6 218.9 219.1 218.9 212.6 218.4 230.7
Diluted earnings per share attributable to Biogen Inc. 212.0 211.8 212.2 215.9 217.0 219.4 219.4 219.3 213.0 218.8 231.2
[1] (1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.